| 1 |
Falk RJ, Jennette C, Nachman PH. Primary glomerular diseases[M]. Brenner BM，Rector FC Jr(eds): The Kidney.7th ed. Philadelphia: WB Saunders, 2004l: l 293-1296.
|
| 2 |
Cui Z, Zhao MH, Wang SX, et al. Concurrent antiglomerular basement membrane disease and immune complex glomerulonephritis[J].Ren Fail, 2006, 28(1): 7-14.
|
| 3 |
Cui Z. Zhao MH.Xin G, et al. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin Praet, 2005, 99(2): 49-55.
|
| 4 |
Yang R, Cui Z, Hellmark T, et al. Natura1 anti GBM antibodies from normal human sera recognize alpha3(IV)NCI restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease. Clin Immunol, 2007, 124(2):207-212.
|
| 5 |
Levy JB, Turner AN, Rees AJ, et al. Long-term outcome of antiglomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med, 2001,134(11): 1033-1042.
|
| 6 |
Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies.Kidney Int, 2004, 66(4): 1535-1540.
|
| 7 |
Hu W, Liu Z, Ji D, et al. Staphylococcal protein A immunoadsorption for Goodpasture's syndrome in four Chinese patients. J Nephrol. 2006 May-Jun;19(3):312-7.
|
| 8 |
De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.Ann Intern Med, 2009, 150(10): 670-680.
|
| 9 |
Kiykim AA, Horoz M, Gok E. Successful treatment of resistant antiglomerular basement membrane antibody positivity with mycophenolic acid. Intern Med, 2010, 49(6): 577-580.
|
| 10 |
Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis, 2002, 61(10):922-924.
|
| 11 |
Levy JB, Lachmann RH, Pusey CD. Recurrent Goodpasture's disease. Am J Kidney Dis, 1996, 27(4): 573-578.
|
| 12 |
Hirayama K, Yamagata K, Kobayashi M, et al. Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol, 2008, 12(5): 339-347.
|
| 13 |
Hind CR, Bowman C, Winearls CG, et al. Recurrence of circulating anti-glomerular basement membrane antibody three years after immunosuppressive treatment and plasma exchange.Clin Nephrol, 1984, 21(4): 244-246.
|
| 14 |
Li FK, Tse KC, Lam MF, et al. Incidence and outcome of antiglomerular basement membrane disease in Chinese.Nephrology (Carlton), 2004, 9(2): 100-104.
|
| 15 |
Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant, 2006, 6(11): 2535-2542.
|
| 16 |
Johnson JP, Moore J Jr, Austin HA, et al. Therapy of antiglomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore), 1985, 64(4): 219-227.
|
| 17 |
Kidney Disease: Improving Global Outcomes (KDIGO)Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int, 2012, 2(Suppl):240-242.
|